Samarium-153-lexidronam for bone pain due to skeletal metastases
Medical Services Advisory Committee
Record ID 31999009756
English
Authors' objectives:
This report summarises the assessment of current evidence for samarium-153-lexidronam injection for the treatment of bone pain in patients with skeletal metastases.
Authors' recommendations:
On the basis of evidence supporting its safety, effectiveness and cost-effectiveness, the supporting committee for this application recommends that Sm-153-lexidronam be subsidised for the relief of bone pain in patients with skeletal metastases (as indicated by a positive bone scan) from the following malignancies:
i. carcinoma of the prostate, where hormonal therapy has failed; or
ii. carcinoma of the breast, where hormonal therapy and chemotherapy have failed; and either:
a. the disease is poorly controlled by conventional radiotherapy; or
b. conventional radiotherapy is inappropriate, due to the wide distribution of sites of bone pain.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.health.gov.au/haf/msac
Year Published:
1999
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Australia
MeSH Terms
- Analgesics, Non-Narcotic
- Neoplasm Metastasis
- Bone Neoplasms
- Pain
- Samarium
Contact
Organisation Name:
Medical Services Advisory Committee
Contact Address:
MSAC (MDP 107), GPO Box 9848, Canberra, ACT 2601, Australia. Tel: +61 2 6289 6811; Fax: +61 2 6289 8799.
Contact Name:
msac.secretariat@health.gov.au
Contact Email:
msac.secretariat@health.gov.au
Copyright:
Medical Services Advisory Committee
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.